Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
May 09 2023 - 10:33AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
May 9, 2023
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
Form 20-F [X] |
Form 40-F [ ] |
Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 9 May
2023 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s
board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to
publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons.
Please find below a statement of such trading in shares issued by Novo Nordisk.
1 |
Details
of the person discharging managerial responsibilities/person closely associated |
a) |
Name of the Board |
Douglas Langa |
|
member/Executive/Associated Person |
|
2 |
Reason for the notification |
a) |
Position/status |
Executive Vice President, head of North America Operations |
b) |
Initial notification/Amendment |
Initial notification |
3 |
Details of the issuer |
a) |
Name |
Novo Nordisk A/S |
b) |
LEI |
549300DAQ1CVT6CXN342 |
4 |
Details of the transaction(s) |
Novo Nordisk A/S
Investor Relations |
Novo Allé
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
Internet:
www.novonordisk.com
CVR no:
24 25 67 90 |
|
|
Company announcement No 31/ 2023 |
a) |
Description of the financial instrument, |
Shares |
|
|
type of instrument, |
|
|
|
|
|
|
|
|
|
|
|
Identification code |
Novo Nordisk B DK0060534915 |
|
b) |
Nature of the transaction |
Sale
of shares |
|
c) |
Price(s) and volume(s) |
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
DKK 1,142.80 |
13,979 shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
d) |
Aggregated information |
|
|
|
|
|
· Aggregated volume |
13,979 shares |
|
|
· Price |
DKK 1,142.80 |
|
e) |
Date of the transaction |
2023-05-08 |
|
f) |
Place of the transaction |
Nasdaq Copenhagen |
|
|
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat
diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific
breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 57,100
people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B).
Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn and
YouTube.
Contact for further information
Media: |
|
Ambre James-Brown
+45 3079 9289
abmo@novonordisk.com |
Natalia Salomao Abrahao
(US)
+1 848 304 1027
niaa@novonordisk.com |
|
|
|
|
Investors: |
|
Daniel Muusmann
Bohsen
+45 3075 2175
dabo@novonordisk.com |
Jacob Martin Wiborg
Rode
+45 3075 5956
jrde@novonordisk.com |
|
|
David Heiberg Landsted
+45 3077 6915
dhel@novonordisk.com |
Mark Joseph Root (US)
+1 848 213 3219
mjhr@novonordisk.com |
Novo Nordisk A/S
Investor Relations |
Novo Allé
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
Internet:
www.novonordisk.com
CVR no:
24 25 67 90 |
|
|
Company announcement No 31/ 2023 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: May 9, 2023 |
NOVO NORDISK A/S
Lars Fruergaard Jørgensen
Chief Executive Officer |
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
From Jul 2023 to Jul 2024